Atlantic Family Wealth LLC Acquires New Holdings in Johnson & Johnson (NYSE:JNJ)

Atlantic Family Wealth LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,536 shares of the company’s stock, valued at approximately $222,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. AMF Tjanstepension AB grew its position in Johnson & Johnson by 14.2% in the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock valued at $68,985,000 after acquiring an additional 52,997 shares in the last quarter. Wealth Group Ltd. acquired a new position in Johnson & Johnson in the 3rd quarter valued at about $213,000. Swedbank AB grew its position in Johnson & Johnson by 5.3% in the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock valued at $358,980,000 after acquiring an additional 111,570 shares in the last quarter. Smithbridge Asset Management Inc. DE grew its position in Johnson & Johnson by 1.3% in the 3rd quarter. Smithbridge Asset Management Inc. DE now owns 40,715 shares of the company’s stock valued at $6,598,000 after acquiring an additional 527 shares in the last quarter. Finally, Welch Group LLC grew its position in Johnson & Johnson by 2.6% in the 3rd quarter. Welch Group LLC now owns 345,797 shares of the company’s stock valued at $56,040,000 after acquiring an additional 8,701 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on JNJ. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Citigroup lowered their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Guggenheim boosted their price objective on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Morgan Stanley lowered their price objective on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Finally, Stifel Nicolaus lowered their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $162.75 on Thursday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a 50 day moving average of $150.08 and a two-hundred day moving average of $155.97. The stock has a market cap of $391.83 billion, a P/E ratio of 24.47, a P/E/G ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter in the prior year, the business earned $2.29 earnings per share. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.05%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.